Literature DB >> 28591578

PLK1 Activation in Late G2 Sets Up Commitment to Mitosis.

Lilia Gheghiani1, Damarys Loew2, Bérangère Lombard2, Jörg Mansfeld3, Olivier Gavet4.   

Abstract

Commitment to mitosis must be tightly coordinated with DNA replication to preserve genome integrity. While we have previously established that the timely activation of CyclinB1-Cdk1 in late G2 triggers mitotic entry, the upstream regulatory mechanisms remain unclear. Here, we report that Polo-like kinase 1 (Plk1) is required for entry into mitosis during an unperturbed cell cycle and is rapidly activated shortly before CyclinB1-Cdk1. We determine that Plk1 associates with the Cdc25C1 phosphatase and induces its phosphorylation before mitotic entry. Plk1-dependent Cdc25C1 phosphosites are sufficient to promote mitotic entry, even when Plk1 activity is inhibited. Furthermore, we find that activation of Plk1 during G2 relies on CyclinA2-Cdk activity levels. Our findings thus elucidate a critical role for Plk1 in CyclinB1-Cdk1 activation and mitotic entry and outline how CyclinA2-Cdk, an S-promoting factor, poises cells for commitment to mitosis.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cdc25C; CyclinA2; FRET biosensor; G2 phase; Plk1; mitosis

Mesh:

Substances:

Year:  2017        PMID: 28591578     DOI: 10.1016/j.celrep.2017.05.031

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  50 in total

1.  Re-investigating PLK1 inhibitors as antimitotic agents.

Authors:  Quentin Delacour; Olivier Gavet
Journal:  Mol Cell Oncol       Date:  2017-08-01

2.  Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials.

Authors:  Yueh-Chwen Hsu; Tsung-Chih Chen; Chien-Chin Lin; Chang-Tsu Yuan; Chia-Lang Hsu; Hsin-An Hou; Chein-Jun Kao; Po-Han Chuang; Yu-Ren Chen; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Blood Adv       Date:  2019-08-13

3.  Nuclear tension controls mitotic entry by regulating cyclin B1 nuclear translocation.

Authors:  Margarida Dantas; Andreia Oliveira; Paulo Aguiar; Helder Maiato; Jorge G Ferreira
Journal:  J Cell Biol       Date:  2022-10-12       Impact factor: 8.077

Review 4.  Recent Progress on the Localization of PLK1 to the Kinetochore and Its Role in Mitosis.

Authors:  Taekyung Kim
Journal:  Int J Mol Sci       Date:  2022-05-08       Impact factor: 6.208

5.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.

Authors:  Faycal Guedj; Ashley E Siegel; Jeroen L A Pennings; Fatimah Alsebaa; Lauren J Massingham; Umadevi Tantravahi; Diana W Bianchi
Journal:  Am J Hum Genet       Date:  2020-10-23       Impact factor: 11.025

6.  Efficacy of adavosertib therapy against anaplastic thyroid cancer.

Authors:  Yu-Ling Lu; Yu-Tung Huang; Ming-Hsien Wu; Ting-Chao Chou; Richard J Wong; Shu-Fu Lin
Journal:  Endocr Relat Cancer       Date:  2021-04-29       Impact factor: 5.678

7.  PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.

Authors:  Lilia Gheghiani; Lei Wang; Youwei Zhang; Xavier T R Moore; Jinglei Zhang; Steven C Smith; Yijun Tian; Liang Wang; Kristi Turner; Colleen K Jackson-Cook; Nitai D Mukhopadhyay; Zheng Fu
Journal:  Cancer Res       Date:  2020-12-29       Impact factor: 13.312

8.  Overlapping roles for PLK1 and Aurora A during meiotic centrosome biogenesis in mouse spermatocytes.

Authors:  Stephen R Wellard; Yujiao Zhang; Chris Shults; Xueqi Zhao; Matthew McKay; Stephen A Murray; Philip W Jordan
Journal:  EMBO Rep       Date:  2021-02-21       Impact factor: 8.807

9.  Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models.

Authors:  Pethaiah Gunasekaran; Min Su Yim; Mija Ahn; Nak-Kyun Soung; Jung-Eun Park; Jaehi Kim; Geul Bang; Sang Chul Shin; Joonhyeok Choi; Minkyoung Kim; Hak Nam Kim; Young-Ho Lee; Young-Ho Chung; Kyeong Lee; Eunice EunKyeong Kim; Young-Ho Jeon; Min Ju Kim; Kyeong-Ryoon Lee; Bo-Yeon Kim; Kyung S Lee; Eun Kyoung Ryu; Jeong Kyu Bang
Journal:  J Med Chem       Date:  2020-11-03       Impact factor: 7.446

10.  Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer.

Authors:  Yu-Ling Lu; Ming-Hsien Wu; Yi-Yin Lee; Ting-Chao Chou; Richard J Wong; Shu-Fu Lin
Journal:  Cancers (Basel)       Date:  2021-07-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.